Electrons spiral with a purpose: A new platform decodes their selective spin
By combining the principles of physics, chemistry, and biology, scientists have crafted a special programmable platform to explore one of the most puzzling quantum mysteries of our time: why electrons seem to choose sides when passing through certain twisted molecules.
This behavior, known as the chiral-induced spin selectivity (CISS) effect, has baffled researchers for over two decades. It shows up in biological processes like photosynthesis and cellular respiration, yet no one fully understands how or why it happens.
Now, researchers from the University of Pittsburgh have engineered an artificial, controllable system that can mimic the conditions under which this strange effect occurs. Their approach could reshape how we study quantum transport and might also help us design new materials for electronics, energy, and even medicine.
"The beauty of our approach is not that it mimics chemistry or biology exactly, but that it allows us to isolate and study individual processes that are relevant in chiral quantum transport," said François Damanet, a physicist and one of the members of the research team.
Back in the late 1990s, scientists Ron Naaman and David Waldeck made a surprising discovery. When electrons pass through films of chiral (twisted) molecules, how easily they can move is decided by their spin, which is a quantum property. Instead of a small noticeable effect, they saw spin-dependent changes as high as 20 percent, a result that stunned the scientific community.
Since then, the CISS effect has popped up in various biological systems, yet researchers haven't been able to pin down the exact mechanism behind it. This is because real biological molecules are complex. They're soft, flexible, constantly moving, and surrounded by water, all of which makes it nearly impossible to isolate the role of chirality alone.
That's where the new platform comes in. The researchers did not try to recreate biology. Instead, they built a clean, programmable playground for electrons. Using a technique developed in 2008, they worked with a special material made from layers of lanthanum aluminate (LaAlO3) and strontium titanate (SrTiO3).
By using a fine-tipped microscopic pen, they could draw paths where electrons can travel. To make those paths chiral, they introduced a clever twist: the probe not only moved in a wavy, serpentine pattern across the surface, but its voltage was also modulated up and down in sync. This combination created spiral-like channels that broke mirror symmetry, the key ingredient of chirality.
These artificial chiral waveguides weren't just pretty shapes. When electrons flowed through them, surprising quantum effects emerged. The team saw unusual conductance patterns and even observed electrons pairing up in ways that shouldn't be possible under strong magnetic fields.
Theoretical models suggested that the spiral geometry created a kind of engineered spin-orbit coupling, which locked the electrons' spin to their direction of motion, just like some theories had proposed for the CISS effect in molecules.
What makes this platform so powerful is that it's fully programmable. Researchers can change the shape, size, and strength of the chiral patterns, erase them, and write new ones, all on the same device. "We can systematically vary parameters like the pitch, amplitude, and coupling strength of chiral modulations—something impossible with fixed structures," Damanet said.
This new platform doesn't try to copy molecules atom-for-atom. Instead, it gives scientists something they've never had before: precise control. In biological systems, everything is messy—molecules wiggle, environments shift, and vibrations interfere with measurements.
However, on this programmable platform, each variable can be changed independently, allowing researchers to test exactly how chirality affects quantum transport. This could help settle long-standing debates about whether spin-orbit interactions, molecular vibrations, or other mechanisms drive the CISS effect.
While the system operates at ultra-cold temperatures and uses inorganic materials, it sets the stage for future hybrid setups that could combine these solid-state tools with real molecules.
The team is already exploring ways to pair their platform with organic materials or carbon nanotubes, and even to run experiments at higher temperatures. The goal isn't to replace biological studies, but to work alongside them, much like how wind tunnels help engineers test aircraft designs before real-world flights.
If successful, this approach could help scientists not only solve the CISS puzzle but also understand other complex quantum systems. It could inspire new materials for spintronics, where electron spin is used in computing, or guide the design of efficient catalysts and bio-inspired energy devices.
The study is published in the journal Science Advances.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
NASA Satellite Glimpses Giant Volcano Peeking Above The Clouds of Mars
A spacecraft's-eye view over the landscapes of Mars has just given us a first-of-its-kind glimpse of the giant, ancient edifice known as Arsia Mons. The NASA satellite Odyssey captured the enormous equatorial volcano as its tip peeked above the morning clouds of water ice – a common feature at this time of the Martian year, when the red planet is at its furthest point from the Sun on its slightly elliptical orbit. Arsia Mons belongs to a volcanic complex known as the Tharsis Montes; three shield volcanoes very close together in the Tharsis region of Mars. Arsia Mons is the tallest of the three, standing at a towering height of nearly 20 kilometers (12 miles). That's dramatically higher than any mountain on Earth, where the tallest peak above sea level (Mount Everest) stands 8.85 kilometers high and the tallest mountain, Mauna Kea, rises 9 kilometers above the sea floor. It also has around 30 times more volume than Earth's largest volcano, Mauna Loa – and it's not even the biggest volcano on Mars. Its activity is thought to have lasted billions of years, peaking around 150 million years ago. Odyssey usually has its cameras pointed down toward the surface of Mars. To obtain the new panorama, it had to rotate 90 degrees so that its camera pointed at the horizon. This angle is worth the effort: it allows scientists to make out layers and clouds in the thin Martian sky to better understand its atmospheric dynamics and processes. Clouds form around Arsia Mons when expanding air rises up the slopes of the mountain, rapidly cooling, allowing ice crystals to form. At Mars's current position in its journey around the Sun, a belt of clouds forms around the equator known as the aphelion cloud belt. Curiosity captured this phenomenon from the surface several years ago; the new Odyssey panorama gives us a spectacular view from above. "We picked Arsia Mons hoping we would see the summit poke above the early morning clouds," says aerospace engineer Jonathon Hill of Arizona State University. "And it didn't disappoint." The Universe's Missing Black Holes May Have Been Located Mysteriously Magnetic Moon Rocks Might Have an Explosive Origin Story Fiery Orange Gems From The Moon Reveal Secrets of Its Violent Past
Yahoo
an hour ago
- Yahoo
Stanford Doctors Invent Device That Appears to Be Able to Save Tons of Stroke Patients Before They Die
Researchers have developed a novel device that literally spins away the clots that block blood flow to the brain and cause strokes. As Stanford explains in a blurb, the novel milli-spinner device may be able to save the lives of patients who experience "ischemic stroke" from brain stem clotting. Traditional clot removal, a process known as thrombectomy, generally uses a catheter that either vacuums up the blood blockage or uses a wire mesh to ensnare it — a procedure that's as rough and imprecise as it sounds. Conventional thrombectomy has a very low efficacy rate because of this imprecision, and the procedure can result in pieces of the clot breaking off and moving to more difficult-to-reach regions. Thrombectomy via milli-spinner also enters the brain with a catheter, but instead of using a normal vacuum device, it employs a spinning tube outfitted with fins and slits that can suck up the clot much more meticulously. Stanford neuroimaging expert Jeremy Heit, who also coauthored a new paper about the device in the journal Nature, explained in the school's press release that the efficacy of the milli-spinner is "unbelievable." "For most cases, we're more than doubling the efficacy of current technology, and for the toughest clots — which we're only removing about 11 percent of the time with current devices — we're getting the artery open on the first try 90 percent of the time," Heit said. "This is a sea-change technology that will drastically improve our ability to help people." Renee Zhao, the senior author of the Nature paper who teaches mechanical engineering at Stanford and creates what she calls "millirobots," said that conventional thrombectomies just aren't cutting it. "With existing technology, there's no way to reduce the size of the clot," Zhao said. "They rely on deforming and rupturing the clot to remove it." "What's unique about the milli-spinner is that it applies compression and shear forces to shrink the entire clot," she continued, "dramatically reducing the volume without causing rupture." Indeed, as the team discovered, the device can cut and vacuum up to five percent of its original size. "It works so well, for a wide range of clot compositions and sizes," Zhao said. "Even for tough... clots, which are impossible to treat with current technologies, our milli-spinner can treat them using this simple yet powerful mechanics concept to densify the fibrin network and shrink the clot." Though its main experimental use case is brain clot removal, Zhao is excited about its other uses, too. "We're exploring other biomedical applications for the milli-spinner design, and even possibilities beyond medicine," the engineer said. "There are some very exciting opportunities ahead." More on brains: The Microplastics in Your Brain May Be Causing Mental Health Issues